Research tools
CRP articles covering C-reactive protein blood testing, inflammation monitoring, treatment response, and IBD research. Research context emphasizes studies, trials, biomarkers, mechanisms, and emerging IBD science.
Page 2 of 2 · 85 articles
1) People with IBD are known to have higher cardiovascular risk; this study directly assessed subclinical carotid atherosclerosis to see if plaque burden explains that risk.
The study tests whether a simple blood-derived index (CRP×NLR) can help identify moderate-to-severe endoscopic inflammation when timely endoscopy is limited in hospitalized UC patients.
The T&W criteria are still used to define severe UC on admission, but relying on them alone may delay recognition of steroid non‑response and escalation decisions. Integrating biomarkers, endoscopy, and imaging can help...
If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.
The study suggests most adults with chronic diarrhea in this tertiary setting had organic/inflammatory disease and identifies accessible clinical and lab predictors that could help prioritize endoscopic evaluation.
People with IBD who have no or few symptoms but still have moderate–severe inflammation on endoscopy face uncertainty about whether to switch therapies to aim for endoscopic remission.
Researchers and clinicians are increasingly studying combinations of IBD drugs because single‑drug remission rates have plateaued; dual therapy may improve outcomes for patients who have failed prior treatments.
Real‑world studies of ustekinumab help patients and clinicians understand how the drug performs outside clinical trials, including effectiveness for steroid‑free remission and use across different UK care settings.
The criteria were tested specifically in patients with psoriasis, uveitis, or IBD presenting with chronic back pain—groups at higher risk of axSpA—so results inform how well the new criteria perform in these real‑world...
The study provides real-world effectiveness and safety data for risankizumab in a largely difficult-to-treat Crohn's population, showing about half achieved corticosteroid-free clinical remission at 24 weeks —...
Combination (dual) therapy is an active area of research because many people with Crohn’s disease don’t achieve lasting remission on a single advanced therapy. New trials suggest some combinations may improve remission...
The study tests whether adding MRI-based transmural assessment to a fecal-calprotectin–guided (CALM) strategy improves the ability to keep people with Crohn’s disease in corticosteroid-free clinical remission and may...
The study suggests nickel accumulation and iron deficiency may be linked with more severe IBD. If confirmed, blood metal and micronutrient levels could help researchers understand disease mechanisms and guide nutritional...
The 1955 Truelove and Witts criteria do not account for patients already on modern outpatient therapies. Updated consensus criteria could change how ASUC is recognized and triaged in current clinical practice.
An externally validated, simple prediction score could help identify patients unlikely to need early aggressive treatment and inform shared decision-making about monitoring and therapy.
For patients and clinicians facing steroid- and infliximab-refractory acute severe ulcerative colitis, upadacitinib may be a third-line medical option that can produce rapid symptom and CRP improvement and allow some...
Exercise is a low-cost, accessible intervention that may improve quality of life and reduce symptoms in people with IBD. This pooled analysis suggests some exercise types — especially regular continuous aerobic exercise...
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
Lowering the CRP cutoff could help hospitals identify hospitalized UC patients at higher risk of needing surgery who are currently classified as less severe. That may affect monitoring and treatment decisions during...
Proactive TDM of infliximab was associated with high 1‑ and 2‑year durability in this pediatric Crohn's cohort, and the study flags clinical factors that may predict need to switch biologics. This could be relevant when...
Markers of systemic inflammation (CRP and ESR) were consistently higher in people with obesity across Crohn’s disease, ulcerative colitis, psoriasis, and psoriatic arthritis, suggesting body weight may influence...
Patients and clinicians choosing first‑line biologic therapy for ulcerative colitis may find evidence here that vedolizumab can provide sustained clinical benefit and a favorable safety profile in a biologic‑naïve...
Bowel urgency is a common, disruptive UC symptom; this trial analysis shows urgency improvements with etrasimod track with clinical remission, endoscopic improvement, better quality of life, and lower inflammatory...
Many patients and clinicians are interested in subcutaneous infliximab because it can be more convenient than IV infusions and may change drug exposure.
People with IBD and their clinicians want ways to predict which advanced therapy will work best. This review summarizes current evidence and shows that, despite many studies, no biomarker is reliably ready for routine...
Noninvasive blood biomarkers that track IBD activity could reduce reliance on repeat endoscopy. If validated, serum galectin‑3 might complement fecal calprotectin and CRP to help identify active disease.
This study suggests that higher intake of specific fibers (beta‑glucan and inulin) may be linked to lower Crohn’s risk in people with a family history, and it connects those fibers to biomarkers of inflammation, barrier...
Vitamin D supplementation is commonly considered in people with IBD because deficiency is frequent and low vitamin D may relate to inflammation.
The study suggests upadacitinib may improve both symptoms and MRI‑documented healing of perianal fistulas in Crohn’s disease, offering a potential treatment option especially for patients who have not previously received...
This study reports real-world data on mirikizumab in adults with ulcerative colitis, focusing on clinical and endoscopic remission and inflammatory markers — outcomes patients and clinicians use to judge treatment...
Understanding and quantifying placebo-driven endoscopic changes can improve design and interpretation of Crohn’s disease trials, which may ultimately speed development of effective therapies and clarify who benefits from...
This study looks at upadacitinib in people with Crohn’s disease who did not respond to anti-TNF drugs — a common and challenging clinical situation.
New oral TYK2 inhibitor data show promise on endoscopic healing and inflammatory markers in Crohn’s disease, which is important because oral treatment options are limited. However, the trial missed its main symptom-based...
Early Phase 2 data suggest VTX958 may improve endoscopic healing and lower inflammatory markers in Crohn’s disease, outcomes that matter for long-term disease control. The report also notes the trial missed its primary...
This reports Phase 2 clinical data for an oral TYK2 inhibitor (VTX958) in Crohn’s disease — a potential new oral treatment approach. The drug showed meaningful endoscopic improvements and reductions in inflammatory...
Diet is a modifiable factor that may influence inflammation and the gut microbiome. If the Mediterranean diet is linked with lower disease activity and inflammatory markers in newly diagnosed Crohn’s disease, patients...
If you have Crohn’s disease, this study suggests following a Mediterranean-style diet may be linked with lower inflammation and a gentler disease course, and it could positively change the gut microbiome and metabolites.
